GB0724051D0 - Mutant proteins and methods for producing them - Google Patents

Mutant proteins and methods for producing them

Info

Publication number
GB0724051D0
GB0724051D0 GBGB0724051.8A GB0724051A GB0724051D0 GB 0724051 D0 GB0724051 D0 GB 0724051D0 GB 0724051 A GB0724051 A GB 0724051A GB 0724051 D0 GB0724051 D0 GB 0724051D0
Authority
GB
United Kingdom
Prior art keywords
producing
methods
mutant proteins
mutant
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0724051.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB0724051.8A priority Critical patent/GB0724051D0/en
Publication of GB0724051D0 publication Critical patent/GB0724051D0/en
Priority to JP2010536531A priority patent/JP2011505800A/ja
Priority to DK08856833.2T priority patent/DK2220229T3/da
Priority to AU2008332896A priority patent/AU2008332896B2/en
Priority to US12/746,674 priority patent/US8748182B2/en
Priority to GB1000387.9A priority patent/GB2467830B/en
Priority to ES12196192T priority patent/ES2972473T3/es
Priority to PL12196192.4T priority patent/PL2568045T3/pl
Priority to CA2708037A priority patent/CA2708037C/en
Priority to EP12196192.4A priority patent/EP2568045B1/en
Priority to PCT/GB2008/004032 priority patent/WO2009071914A2/en
Priority to EP08856833.2A priority patent/EP2220229B1/en
Priority to JP2015032798A priority patent/JP6567291B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1058Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Ecology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
GBGB0724051.8A 2007-12-08 2007-12-08 Mutant proteins and methods for producing them Ceased GB0724051D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0724051.8A GB0724051D0 (en) 2007-12-08 2007-12-08 Mutant proteins and methods for producing them
EP08856833.2A EP2220229B1 (en) 2007-12-08 2008-12-08 Mutant g-protein coupled receptors and methods for selecting them
ES12196192T ES2972473T3 (es) 2007-12-08 2008-12-08 Receptores acoplados a proteína G mutantes y métodos para elaborarlos
DK08856833.2T DK2220229T3 (da) 2007-12-08 2008-12-08 Mutant g-protein coupled receptors and methods for selecting them
AU2008332896A AU2008332896B2 (en) 2007-12-08 2008-12-08 Mutant proteins and methods for producing them
US12/746,674 US8748182B2 (en) 2007-12-08 2008-12-08 Mutant proteins and methods for producing them
GB1000387.9A GB2467830B (en) 2007-12-08 2008-12-08 Mutant proteins and methods for producing them
JP2010536531A JP2011505800A (ja) 2007-12-08 2008-12-08 変異体タンパク質とその製造方法
PL12196192.4T PL2568045T3 (pl) 2007-12-08 2008-12-08 Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania
CA2708037A CA2708037C (en) 2007-12-08 2008-12-08 Mutant g-protein coupled receptors with increased conformational stability and methods for producing them
EP12196192.4A EP2568045B1 (en) 2007-12-08 2008-12-08 Mutant g-protein coupled receptors and methods for making them
PCT/GB2008/004032 WO2009071914A2 (en) 2007-12-08 2008-12-08 Mutant proteins and methods for producing them
JP2015032798A JP6567291B2 (ja) 2007-12-08 2015-02-23 変異体タンパク質とその製造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0724051.8A GB0724051D0 (en) 2007-12-08 2007-12-08 Mutant proteins and methods for producing them

Publications (1)

Publication Number Publication Date
GB0724051D0 true GB0724051D0 (en) 2008-01-16

Family

ID=38983182

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0724051.8A Ceased GB0724051D0 (en) 2007-12-08 2007-12-08 Mutant proteins and methods for producing them
GB1000387.9A Active GB2467830B (en) 2007-12-08 2008-12-08 Mutant proteins and methods for producing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1000387.9A Active GB2467830B (en) 2007-12-08 2008-12-08 Mutant proteins and methods for producing them

Country Status (10)

Country Link
US (1) US8748182B2 (enExample)
EP (2) EP2220229B1 (enExample)
JP (2) JP2011505800A (enExample)
AU (1) AU2008332896B2 (enExample)
CA (1) CA2708037C (enExample)
DK (1) DK2220229T3 (enExample)
ES (1) ES2972473T3 (enExample)
GB (2) GB0724051D0 (enExample)
PL (1) PL2568045T3 (enExample)
WO (1) WO2009071914A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120336T1 (hr) 2007-03-22 2012-05-31 Heptares Therapeutics Limited Receptori vezani na mutacije g-proteina i metode njihovog odabira
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
WO2012022928A2 (en) * 2010-08-20 2012-02-23 Heptares Therapeutic Ltd Biological materials and uses thereof
US20140031525A1 (en) 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
JP6263773B2 (ja) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜タンパク質およびその調製および使用方法
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
US10458993B2 (en) 2012-06-01 2019-10-29 Heptares Therapeutics Limited Assay for assessing conformational stability of membrane protein
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
US9593157B2 (en) 2013-01-30 2017-03-14 Vib Vzw Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies
WO2014140586A2 (en) 2013-03-15 2014-09-18 Medical Research Council Mutant proteins and methods for their production
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
EP3212784B1 (en) 2014-10-31 2019-05-29 Abilita Bio, Inc. Modified membrane spanning proteins and methods for the preparation and use thereof
US20190144912A1 (en) * 2015-09-04 2019-05-16 The Scripps Research Institute Methods for identifying novel antibiotics and related compositions
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
ES2737307T3 (es) 2016-02-29 2020-01-13 Ose Immunotherapeutics Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
CN109415445A (zh) 2016-05-04 2019-03-01 阿比利塔生物公司 用于制备多跨膜蛋白的方法和平台
WO2018150260A1 (en) * 2017-02-16 2018-08-23 Institut Pasteur Method for the identification of mutated proteins having modified thermal stability

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2001774C (en) 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
JP3147916B2 (ja) 1991-03-08 2001-03-19 森永製菓株式会社 体外免疫方法
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
WO1995032425A1 (en) 1994-05-23 1995-11-30 Smithkline Beecham Corporation Encoded combinatorial libraries
US20020028443A1 (en) 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
WO1997035881A2 (en) 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
AU2728297A (en) 1996-04-15 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain G-protein-coupled receptor compositions and me thods
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US7094593B1 (en) 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
AU782959B2 (en) 1999-11-17 2005-09-15 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
WO2002018590A2 (en) 2000-08-30 2002-03-07 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6448377B1 (en) 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
CA2425149A1 (en) 2000-10-26 2002-08-01 New England Medical Center Hospitals, Inc. Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
CA2439383A1 (en) 2001-02-26 2002-09-06 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
EP2369344B1 (en) * 2001-03-30 2016-11-16 Suntory Holdings Limited Structural model of G protein-coupled receptor and method for designing ligand capable of binding to G protein-coupled receptor using the structural model
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US20030170842A1 (en) 2001-10-25 2003-09-11 Williams Pamela A. Crystals of cytochrome P450 2C9, structures thereof and their use
US7115377B2 (en) 2001-10-26 2006-10-03 Atto Bioscience, Inc. Cell-based assays for G-protein-coupled receptor-mediated activities
JP4344928B2 (ja) 2002-04-24 2009-10-14 萬有製薬株式会社 ヒスタミン受容体h3常活性変異体およびその利用
ATE457728T1 (de) 2002-05-01 2010-03-15 Vertex Pharma Kristallstruktur des aurora-2 proteins und dessen bindungstaschen
US7745161B2 (en) 2003-12-19 2010-06-29 Palo Alto Research Center Incorporated Amplification of enzymatic reactions for use with an enthalpy array
US20060281699A1 (en) * 2004-05-12 2006-12-14 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
WO2006023248A2 (en) 2004-07-28 2006-03-02 The Trustees Of Columbia University In The City Of New York Processes for producing and crystallizing g-protein coupled receptors
US20070154947A1 (en) 2005-08-31 2007-07-05 The Trustees Of Princeton University Chemical biodiscriminator
US20070196389A1 (en) 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
HRP20120336T1 (hr) 2007-03-22 2012-05-31 Heptares Therapeutics Limited Receptori vezani na mutacije g-proteina i metode njihovog odabira
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
EP2284207B1 (en) * 2008-05-30 2012-07-04 Asahi Glass Company, Limited Hard foam synthetic resin and process for producing the same
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
WO2012022928A2 (en) 2010-08-20 2012-02-23 Heptares Therapeutic Ltd Biological materials and uses thereof

Also Published As

Publication number Publication date
CA2708037A1 (en) 2009-06-11
JP2015133973A (ja) 2015-07-27
CA2708037C (en) 2018-09-18
JP6567291B2 (ja) 2019-08-28
WO2009071914A3 (en) 2009-10-15
AU2008332896A1 (en) 2009-06-11
DK2220229T3 (da) 2020-09-07
EP2220229B1 (en) 2020-06-24
AU2008332896B2 (en) 2014-05-08
PL2568045T3 (pl) 2024-05-13
WO2009071914A2 (en) 2009-06-11
ES2972473T3 (es) 2024-06-12
JP2011505800A (ja) 2011-03-03
GB201000387D0 (en) 2010-02-24
EP2568045B1 (en) 2024-01-24
EP2220229A2 (en) 2010-08-25
US20110028700A1 (en) 2011-02-03
GB2467830B (en) 2013-05-15
GB2467830A (en) 2010-08-18
EP2568045A1 (en) 2013-03-13
US8748182B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
GB2467830B (en) Mutant proteins and methods for producing them
GB0910725D0 (en) Mutant proteins and methods for producing them
GB0802474D0 (en) Mutant proteins and methods for selecting them
GB2449991B (en) Non-bolt joint structure and method for producing non-bolt joint structure
EP2121756A4 (en) ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
EP2009504A4 (en) TONER AND METHOD FOR PRODUCING THE SAME
IL192098A (en) Preparations and Methods for Manufacturing Preparations
IL202183A0 (en) Anti-notch1 nrr antibodies and methods using same
GB2428265B (en) Methods and apparatus for optimizing well production
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
EP1987724A4 (en) FOOD AND METHOD FOR PRODUCING A FOOD
ZA200810460B (en) Modified beta-lactamase and method for its preparation
EP2234626A4 (en) METHOD AND MEANS FOR PRODUCING BRONCHORELAXATION
IL231891A0 (en) Anti-2ephriinb antibodies and methods of using them
TWI370107B (en) Novel methods for making and using halosilylgermanes
PL2007943T3 (pl) Tkaniny odporne na promieniowanie ultrafioletowe i sposoby ich wytwarzania
EP1972615A4 (en) CYCLOALCANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING THE SAME
AP2009005063A0 (en) Modified wood and method for producing modified wood
GB0622342D0 (en) Novel compounds and methods for their production
GB0901109D0 (en) Mutant proteins and methods for selecting them
ZA200809008B (en) 2-alkenyl-3-aminothipene derivative and process for producing thereof
EP2126088A4 (en) VECTORS AND METHODS FOR ENZYME PRODUCTION
GB0706637D0 (en) Compression method and means
EP2014807A4 (en) CARPET AND MANUFACTURING METHOD THEREFOR
ZA200806053B (en) Anti-EphB4 antibodies and methods using same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)